Clareo Health | Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Leon Berard
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
I1. Confirmed diagnosis of any type of solid or hematologic tumor;
I2. Ongoing anticancer treatment (cytotoxic, targeted therapy, immunotherapy or loco regional procedure, including radiotherapy, surgery or interventional radiology procedure) at the time of inclusion or within the last 3 months prior to inclusion (last treatment administration or last loco regional procedure) ;
I3. Patient with suspicion of COVID-19 (clinical symptoms of COVID-19 including fever (\>38°C) and/or respiratory tract symptoms), either confirmed or not.
Note 1: Patients must have underwent diagnostic procedures: diagnostic test (positive or negative) and/or chest imaging. Note 2: Patients will be eligible regardless of the presence of a neutropenia (either febrile or not) ;
I4. Patient and/or family did not decline data collection after complete information.
